Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer

Lurbinectedin is a DNA-binding inhibitor of transcription that potently induces immunogenic cell death (ICD). In June 2020, the Federal Drug Administration (FDA) approved lurbinectedin for the salvage treatment of small-cell lung cancer that has relapsed from platinum compound-based first-line chemo...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology
Main Authors: Kepp, Oliver, Zitvogel, Laurence, Kroemer, Guido
Format: Artigo
Language:Inglês
Published: Taylor & Francis 2020
Subjects:
Editorial
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7458590/
https://ncbi.nlm.nih.gov/pubmed/32923159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1795995
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items